Formerly known as Calzada, PolyNovo has won approval from the US Food & Drug Administration to sell NovoSorb, a temporary lattice inserted ahead of an eventual skin graft.
Developed by the CSIRO, NovoSorb is a foam-like sheet that is stapled to the affected area, to encourage the regrowth of normal skin cells. Unlike the prevailing treatment, the burnt area can be unrecognisable from the surrounding skin.
PolyNovo chairman David Williams said the next step was finding a big distribution partner for the product, which will compete in an $US800 million ($1bn) a year market. He said PolyNovo was also pursuing potential applications for a wider $US8bn market including treating diabetic ulcers, hernias and breast implants. “There are some really big markets we are playing around with.’’
Read more: http://www.theaustralian.com.au/business/companies/polynovo-wins-us-fda-approval-for-burns-treatment-novosorb/news-story/15791fa080a4ca42538d45fd2a1a885d